Trial Profile
A study to assess efficacy and safety of combination of biologic therapy for different medical conditions
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary) ; Dupilumab (Primary) ; Mepolizumab (Primary) ; Omalizumab (Primary)
- Indications Asthma; Atopic dermatitis; Chronic urticaria
- Focus Adverse reactions; Therapeutic Use
- 13 Apr 2022 New trial record
- 28 Feb 2022 Results presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology